Dublin, Dec. 24, 2024 (GLOBE NEWSWIRE) — The “Myelodysplastic Syndrome (MDS) Drugs – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for Myelodysplastic Syndrome (MDS) Drugs was estimated at US$2.2 Billion in 2023 and is projected to reach US$4.1 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the Myelodysplastic Syndrome drugs market is driven by several factors, including increasing incidence rates, especially among older populations, and advancements in treatment options. The development of targeted therapies and novel combinations is enhancing the therapeutic landscape, providing patients with more effective management of the disease.
Furthermore, improved diagnostic techniques are facilitating earlier detection and better classification of MDS, enabling personalized treatment approaches. Ongoing research and clinical trials exploring the potential of immunotherapies and new drug classes are also contributing to the expansion of the market. Strategic collaborations between research institutions and pharmaceutical companies are accelerating the pace of innovation, driving growth in this field.
Hypomethylating agents account for the largest share due to their established role in managing MDS, but the growth factor segment is also significant, especially for managing anemia associated with the disease. Treatment types include supportive care, low-intensity therapy, and high-intensity therapy, with supportive care continuing to play a crucial role in MDS management. By distribution channel, hospital pharmacies dominate the market, though specialty pharmacies are seeing growth due to the increasing complexity of MDS treatment. North America remains the largest market due to higher MDS incidence and access to advanced healthcare.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Immunomodulatory Drugs segment, which is expected to reach US$2.7 Billion by 2030 with a CAGR of a 9.4%. The Hypomethylating Agents segment is also set to grow at 5.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $585.1 Million in 2023, and China, forecasted to grow at an impressive 13.7% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Questions Answered:
- How is the Global Myelodysplastic Syndrome (MDS) Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Global Myelodysplastic Syndrome (MDS) Drugs Market such as Amgen, BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Johnson & Johnson and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 34 companies featured in this Myelodysplastic Syndrome (MDS) Drugs market report include:
- Amgen
- BluePoint Laboratories
- Celgene Corporation
- Celgene Europe Limited
- Johnson & Johnson
- Lupin Ltd. Corporation
- Otsuka America Pharmaceutical Inc.
- Reddy’s Laboratories, Inc.
- Sandoz
- Shilpa Medicare Limited
- Sun Pharmaceutical Industries Inc.
- Takeda
Key Attributes
| Report Attribute | Details |
| No. of Pages | 89 |
| Forecast Period | 2023 – 2030 |
| Estimated Market Value (USD) in 2023 | $2.2 Billion |
| Forecasted Market Value (USD) by 2030 | $4.1 Billion |
| Compound Annual Growth Rate | 9.1% |
| Regions Covered | Global |
Key Topics Covered
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Global Economic Update
- Myelodysplastic Syndrome (MDS) Drugs – Global Key Competitors Percentage Market Share in 2024
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Demand for Targeted and Disease-Modifying Therapies Spurs Growth in Myelodysplastic Syndrome Drugs Market
- Technological Advancements in Hypomethylating Agents Strengthen Business Case for Adoption
- Growing Focus on Early Detection and Risk Stratification Expands Addressable Market
- Expansion of MDS Drugs in Hematology and Oncology Centers Fuels Market Growth
- Increasing Adoption of Combination Therapies and Novel Chemotherapies Expands Market Opportunities
- Technological Innovations in Epigenetic Modifiers and Immunomodulatory Drugs Propel Market Expansion
- Rising Focus on Improving Survival Rates and Quality of Life Drives Demand for MDS Drugs
- Growing Use of MDS Drugs in Stem Cell Transplantation and Supportive Care Expands Market Potential
- Focus on Complying with FDA and EMA Approval Pathways Strengthens Market for MDS Drugs
- Rising Adoption of Next-Generation Therapeutics in High-Risk MDS Expands Addressable Market
- Technological Advancements in Precision Medicine and Biomarker-Driven Therapies Propel Market Growth
- Increasing Focus on Managed Access Programs and Compassionate Use Drives Adoption
- Expansion of MDS Drugs in Palliative Care and Symptom Management Expands Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/cszglv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Myelodysplastic Syndrome (MDS) Drugs Market
